Nonalcoholic Fatty Liver Disease: Cytokine-Adipokine Interplay and Regulation of Insulin Resistance

Gastroenterology

Volumn 131, Issue 3, 2006, Pages 934-945

  Tilg, Herbert ^a   Hotamisligil, Gökhan S ^b  

^a INSTITUTE FOR MICROELECTRONICS   (Austria)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; ENDOTOXIN; FATTY ACID; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PIOGLITAZONE; PROBIOTIC AGENT; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ANTIBODY;

APOPTOSIS; ARTICLE; BODY FAT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HORMONAL REGULATION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 33748111665     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.05.054     Document Type: Article

References (130)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Marchesini G., Marzocchi R., Agostini F., and Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16 (2005) 421-427
3. Adams L.A., Angulo P., and Lindor K.D. Nonalcoholic fatty liver disease. CMAJ 172 (2005) 899-905
4. Marchesini G., and Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology 35 (2002) 497-499
5. Bugianesi E., Marzocchi R., Villanova N., and Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol 18 (2004) 1105-1116
6. Tilg H., and Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 343 (2000) 1467-1476
7. Sanyal A.J. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 46-53
8. Wellen K.E., and Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 115 (2005) 1111-1119
9. Gabriely I., and Barzilai N. Surgical removal of visceral adipose tissue: effects on insulin action. Curr Diab Rep 3 (2003) 201-206
10. Malbon C.C. Insulin signalling: putting the "G-" in protein-protein interactions. Biochem J 380 (2004) e11-e12
11. Pirola L., Johnston A.M., and Van Obberghen E. Modulation of insulin action. Diabetologia 47 (2004) 170-184
12. Mizuhara H., O'Neill E., Seki N., Ogawa T., Kusunoki C., Otsuka K., Satoh S., Niwa M., Senoh H., and Fujiwara H. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 179 (1994) 1529-1537
13. Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275 (2000) 2247-2250
14. McClain C.J., Song Z., Barve S.S., Hill D.B., and Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol 287 (2004) G497-G502
15. Akerman P., Cote P., Yang S.Q., McClain C., Nelson S., Bagby G.J., and Diehl A.M. Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. Am J Physiol 263 (1992) G579-G585
16. Cressman D.E., Greenbaum L.E., DeAngelis R.A., Ciliberto G., Furth E.E., Poli V., and Taub R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274 (1996) 1379-1383
17. Yamada Y., Kirillova I., Peschon J.J., and Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A 94 (1997) 1441-1446
18. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., Fernandez-Escalante J.C., and Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34 (2001) 1158-1163
19. Feldstein A.E., Canbay A., Angulo P., Taniai M., Burgart L.J., Lindor K.D., and Gores G.J. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125 (2003) 437-443
20. Ribeiro P.S., Cortez-Pinto H., Sola S., Castro R.E., Ramalho R.M., Baptista A., Moura M.C., Camilo M.E., and Rodrigues C.M. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 99 (2004) 1708-1717
21. Feldstein A.E., Canbay A., Guicciardi M.E., Higuchi H., Bronk S.F., and Gores G.J. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J Hepatol 39 (2003) 978-983
22. Valenti L., Fracanzani A.L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., Fiorelli G., and Fargion S. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 274-280
23. Nehra V., Angulo P., Buchman A.L., and Lindor K.D. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 46 (2001) 2347-2352
24. Feldstein A.E., Werneburg N.W., Canbay A., Guicciardi M.E., Bronk S.F., Rydzewski R., Burgart L.J., and Gores G.J. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40 (2004) 185-194
25. Li Z., Yang S., Lin H., Huang J., Watkins P.A., Moser A.B., Desimone C., Song X.Y., and Diehl A.M. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37 (2003) 343-350
26. Xu H., Hirosumi J., Uysal K.T., Guler A.D., and Hotamisligil G.S. Exclusive action of transmembrane TNF alpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. Endocrinology 143 (2002) 1502-1511
27. Xu H., Uysal K.T., Becherer J.D., Arner P., and Hotamisligil G.S. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes 51 (2002) 1876-1883
28. Borst S.E., and Conover C.F. High-fat diet induces increased tissue expression of TNF-alpha. Life Sci 77 (2005) 2156-2165
29. Katsuki A., Sumida Y., Urakawa H., Gabazza E.C., Murashima S., Maruyama N., Morioka K., Nakatani K., Yano Y., and Adachi Y. Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance. Diabetes Care 26 (2003) 2341-2344
30. Kim J.K., Fillmore J.J., Chen Y., Yu C., Moore I.K., Pypaert M., Lutz E.P., Kako Y., Velez-Carrasco W., Goldberg I.J., Breslow J.L., and Shulman G.I. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98 (2001) 7522-7527
31. Tobe K., Suzuki R., Aoyama M., Yamauchi T., Kamon J., Kubota N., Terauchi Y., Matsui J., Akanuma Y., Kimura S., Tanaka J., Abe M., Ohsumi J., Nagai R., and Kadowaki T. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. J Biol Chem 276 (2001) 38337-38340
32. Maeda K., Cao H., Kono K., Gorgun C.Z., Furuhashi M., Uysal K.T., Cao Q., Atsumi G., Malone H., Krishnan B., Minokoshi Y., Kahn B.B., Parker R.A., and Hotamisligil G.S. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 1 (2005) 107-119
33. Solga S.F., and Diehl A.M. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 38 (2003) 681-687
34. Loguercio C., Federico A., Tuccillo C., Terracciano F., D'Auria M.V., De Simone C., and Del Vecchio B.C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 39 (2005) 540-543
35. Fukui H., Brauner B., Bode J.C., and Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 12 (1991) 162-169
36. Guarner C., and Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 17 (2005) 27-31
37. Wiest R., Das S., Cadelina G., Garcia-Tsao G., Milstien S., and Groszmann R.J. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 104 (1999) 1223-1233
38. Rao R.K., Seth A., and Sheth P. Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol 286 (2004) G881-G884
39. Alexander W.S. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2 (2002) 410-416
40. Chong M.M., Metcalf D., Jamieson E., Alexander W.S., and Kay T.W. Suppressor of cytokine signaling-1 in T cells and macrophages is critical for preventing lethal inflammation. Blood 106 (2005) 1668-1675
41. Rui L., Yuan M., Frantz D., Shoelson S., and White M.F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277 (2002) 42394-42398
42. Emanuelli B., Peraldi P., Filloux C., Chavey C., Freidinger K., Hilton D.J., Hotamisligil G.S., and Van Obberghen E. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276 (2001) 47944-47949
43. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., Nicola N.A., Metcalf D., Hilton D.J., Roberts A.W., and Alexander W.S. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4 (2003) 540-545
44. Senn J.J., Klover P.J., Nowak I.A., Zimmers T.A., Koniaris L.G., Furlanetto R.W., and Mooney R.A. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278 (2003) 13740-13746
45. Ueki K., Kondo T., Tseng Y.H., and Kahn C.R. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci U S A 101 (2004) 10422-10427
46. Howard J.K., Cave B.J., Oksanen L.J., Tzameli I., Bjorbaek C., and Flier J.S. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3. Nat Med 10 (2004) 734-738
47. Banks A.S., Li J., McKeag L., Hribal M.L., Kashiwada M., Accili D., and Rothman P.B. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 115 (2005) 2462-2471
48. Kawaguchi T., Yoshida T., Harada M., Hisamoto T., Nagao Y., Ide T., Taniguchi E., Kumemura H., Hanada S., Maeyama M., Baba S., Koga H., Kumashiro R., Ueno T., Ogata H., Yoshimura A., and Sata M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165 (2004) 1499-1508
49. Pelleymounter M.A., Cullen M.J., Baker M.B., Hecht R., Winters D., Boone T., and Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269 (1995) 540-543
50. Diehl A.M. Fatty liver, hypertension, and the metabolic syndrome. Gut 53 (2004) 923-924
51. Li Z., Lin H., Yang S., and Diehl A.M. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 123 (2002) 1304-1310
52. Chitturi S., Farrell G., Frost L., Kriketos A., Lin R., Fung C., Liddle C., Samarasinghe D., and George J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology 36 (2002) 403-409
53. Leclercq I.A., Farrell G.C., Schriemer R., and Robertson G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 37 (2002) 206-213
54. Oben J.A., Roskams T., Yang S., Lin H., Sinelli N., Li Z., Torbenson M., Thomas S.A., and Diehl A.M. Norepinephrine induces hepatic fibrogenesis in leptin deficient ob/ob mice. Biochem Biophys Res Commun 308 (2003) 284-292
55. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., and Thurman R.G. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117 (1999) 942-952
56. Lin H.Z., Yang S.Q., Chuckaree C., Kuhajda F., Ronnet G., and Diehl A.M. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 6 (2000) 998-1003
57. Solomon S.S., Mishra S.K., Cwik C., Rajanna B., and Postlethwaite A.E. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Horm Metab Res 29 (1997) 379-382
58. Tomita K., Azuma T., Kitamura N., Nishida J., Tamiya G., Oka A., Inokuchi S., Nishimura T., Suematsu M., and Ishii H. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126 (2004) 873-885
59. Ohata M., Suzuki H., Sakamoto K., Hashimoto K., Nakajima H., Yamauchi M., Hokkyo K., Yamada H., and Toda G. Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha. Alcohol Clin Exp Res 28 (2004) 139S-144S
60. Scherer P.E., Williams S., Fogliano M., Baldini G., and Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (1995) 26746-26749
61. Hu E., Liang P., and Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271 (1996) 10697-10703
62. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., Furuyama N., Kondo H., Takahashi M., Arita Y., Komuro R., Ouchi N., Kihara S., Tochino Y., Okutomi K., Horie M., Takeda S., Aoyama T., Funahashi T., and Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (2002) 731-737
63. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., and George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004) 46-54
64. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1999) 79-83
65. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., Iwahashi H., Kuriyama H., Ouchi N., Maeda K., Nishida M., Kihara S., Sakai N., Nakajima T., Hasegawa K., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Hanafusa T., and Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
66. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., Eto K., Yamashita T., Kamon J., Satoh H., Yano W., Froguel P., Nagai R., Kimura S., Kadowaki T., and Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277 (2002) 25863-25866
67. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., Arita Y., Okamoto Y., Shimomura I., Hiraoka H., Nakamura T., Funahashi T., and Matsuzawa Y. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003) 85-89
68. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
69. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., and Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 101 (2004) 10308-10313
70. Lopez-Bermejo A., Botas P., Funahashi T., Delgado E., Kihara S., Ricart W., and Fernandez-Real J.M. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 60 (2004) 256-263
71. Musso G., Gambino R., Biroli G., Carello M., Faga E., Pacini G., De Michieli F., Cassader M., Durazzo M., Rizzetto M., and Pagano G. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100 (2005) 2438-2446
72. Bugianesi E., Pagotto U., Manini R., Vanni E., Gastaldelli A., de Iasio R., Gentilcore E., Natale S., Cassader M., Rizzetto M., Pasquali R., and Marchesini G. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90 (2005) 3498-3504
73. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., Ebenbichler C.F., Patsch J.R., and Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005) 117-121
74. Tietge U.J., Boker K.H., Manns M.P., and Bahr M.J. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol 287 (2004) E82-E89
75. Kaser S., Moschen A., Kaser A., Ludwiczek O., Ebenbichler C.F., Vogel W., Jaschke W., Patsch J.R., and Tilg H. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Intern Med 258 (2005) 274-280
76. Pineiro R., Iglesias M.J., Gallego R., Raghay K., Eiras S., Rubio J., Dieguez C., Gualillo O., Gonzalez-Juanatey J.R., and Lago F. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 579 (2005) 5163-5169
77. Delaigle A.M., Jonas J.C., Bauche I.B., Cornu O., and Brichard S.M. Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology 145 (2004) 5589-5597
78. Wolf A.M., Wolf D., Avila M.A., Moschen A.R., Berasain C., Enrich B., Rumpold H., and Tilg H. Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol 44 (2006) 537-543
79. Fasshauer M., Kralisch S., Klier M., Lossner U., Bluher M., Klein J., and Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301 (2003) 1045-1050
80. Bruun J.M., Lihn A.S., Verdich C., Pedersen S.B., Toubro S., Astrup A., and Richelsen B. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol 285 (2003) E527-E533
81. Keller P., Moller K., Krabbe K.S., and Pedersen B.K. Circulating adiponectin levels during human endotoxaemia. Clin Exp Immunol 134 (2003) 107-110
82. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., and Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52 (2003) 1655-1663
83. He W., Barak Y., Hevener A., Olson P., Liao D., Le J., Nelson M., Ong E., Olefsky J.M., and Evans R.M. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100 (2003) 15712-15717
84. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., Doo E., Ghany M., Premkumar A., Park Y., Liang T.J., Yanovski J.A., Kleiner D.E., and Hoofnagle J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
85. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
86. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., Hotta K., Nishida M., Takahashi M., Nakamura T., Yamashita S., Funahashi T., and Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
87. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., Kihara S., Funahashi T., Tenner A.J., Tomiyama Y., and Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
88. Kumada M., Kihara S., Ouchi N., Kobayashi H., Okamoto Y., Ohashi K., Maeda K., Nagaretani H., Kishida K., Maeda N., Nagasawa A., Funahashi T., and Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109 (2004) 2046-2049
89. Wulster-Radcliffe M.C., Ajuwon K.M., Wang J., Christian J.A., and Spurlock M.E. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316 (2004) 924-929
90. Wolf A.M., Wolf D., Rumpold H., Enrich B., and Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323 (2004) 630-635
91. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
92. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., Fukui K., Maeda N., Nishizawa H., Nagaretani H., Okamoto Y., Kihara S., Miyagawa J., Shinomura Y., Funahashi T., and Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125 (2003) 1796-1807
93. y obese mice. Hepatology 40 (2004) 177-184
94. Sennello J.A., Fayad R., Morris A.M., Eckel R.H., Asilmaz E., Montez J., Friedman J.M., Dinarello C.A., and Fantuzzi G. Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 146 (2005) 2157-2164
95. Hotamisligil G.S., Shargill N.S., and Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259 (1993) 87-91
96. Uysal K.T., Wiesbrock S.M., Marino M.W., and Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389 (1997) 610-614
97. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., and Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95 (1995) 2111-2119
98. Dandona P., Weinstock R., Thusu K., Abdel-Rahman E., Aljada A., and Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83 (1998) 2907-2910
99. Mantzoros C.S., Moschos S., Avramopoulos I., Kaklamani V., Liolios A., Doulgerakis D.E., Griveas I., Katsilambros N., and Flier J.S. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. J Clin Endocrinol Metab 82 (1997) 3408-3413
100. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., Klein S., and Coppack S.W. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82 (1997) 4196-4200
101. Yudkin J.S., Stehouwer C.D., Emeis J.J., and Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
102. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F., and Spiegelman B.M. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271 (1996) 665-668
103. Yin M.J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396 (1998) 77-80
104. Aguirre V., Uchida T., Yenush L., Davis R., and White M.F. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275 (2000) 9047-9054
105. Paz K., Hemi R., LeRoith D., Karasik A., Elhanany E., Kanety H., and Zick Y. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 272 (1997) 29911-29918
106. Sethi J.K., Xu H., Uysal K.T., Wiesbrock S.M., Scheja L., and Hotamisligil G.S. Characterisation of receptor-specific TNFalpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett 469 (2000) 77-82
107. Uysal K.T., Wiesbrock S.M., and Hotamisligil G.S. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 139 (1998) 4832-4838
108. Csehi S.B., Mathieu S., Seifert U., Lange A., Zweyer M., Wernig A., and Adam D. Tumor necrosis factor (TNF) interferes with insulin signaling through the p55 TNF receptor death domain. Biochem Biophys Res Commun 329 (2005) 397-405
109. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., and Shoelson S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293 (2001) 1673-1677
110. Ebstein W. Zur therapie des diabetes mellitus, insbesondere über die anwendung des salicylsauren natron bei demselben. Berl Klin Wochenschrift 13 (2005) 337-340
111. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., and Shoelson S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11 (2005) 183-190
112. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., Wynshaw-Boris A., Poli G., Olefsky J., and Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11 (2005) 191-198
113. Petersen K.F., Dufour S., Befroy D., Garcia R., and Shulman G.I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350 (2004) 664-671
114. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., Tuncman G., Gorgun C., Glimcher L.H., and Hotamisligil G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306 (2004) 457-461
115. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., and Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 420 (2002) 333-336
116. Nguyen M.T., Satoh H., Favelyukis S., Babendure J.L., Imamura T., Sbodio J.I., Zalevsky J., Dahiyat B.I., Chi N.W., and Olefsky J.M. JNK and tumor necrosis factor-{alpha} mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 280 (2005) 35361-35371
117. Makowski L., Brittingham K.C., Reynolds J.M., Suttles J., and Hotamisligil G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 280 (2005) 12888-12895
118. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
119. Daynes R.A., and Jones D.C. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2 (2002) 748-759
120. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
121. Seo J.B., Moon H.M., Kim W.S., Lee Y.S., Jeong H.W., Yoo E.J., Ham J., Kang H., Park M.G., Steffensen K.R., Stulnig T.M., Gustafsson J.A., Park S.D., and Kim J.B. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 24 (2004) 3430-3444
122. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., and Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9 (2003) 213-219
123. Shimomura I., Bashmakov Y., and Horton J.D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274 (1999) 30028-30032
124. Horton J.D., Shimomura I., Ikemoto S., Bashmakov Y., and Hammer R.E. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J Biol Chem 278 (2003) 36652-36660
125. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., and Clore J.N. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
126. Leclercq I.A., Farrell G.C., Field J., Bell D.R., Gonzalez F.J., and Robertson G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105 (2000) 1067-1075
127. Schattenberg J.M., Wang Y., Singh R., Rigoli R.M., and Czaja M.J. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 280 (2005) 9887-9894
128. Xu Z., Chen L., Leung L., Yen T.S., Lee C., and Chan J.Y. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci U S A 102 (2005) 4120-4125
129. Chavin K.D., Yang S., Lin H.Z., Chatham J., Chacko V.P., Hoek J.B., Walajtys-Rode E., Rashid A., Chen C.H., Huang C.C., Wu T.C., Lane M.D., and Diehl A.M. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 274 (1999) 5692-5700
130. Sreekumar R., Rosado B., Rasmussen D., and Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 38 (2003) 244-251